Utility of 99mTc-MAA SPECT/CT for treatment plan of radioembolization using resin microspheres in HCC patients compared with 90Y PET/CT

  • Mai Hong Son 108 Military Central Hospital
  • Nguyen Do Kien 108 Military Central Hospital
  • Nguyen Thi Kim Dung 108 Military Central Hospital
  • Pham Minh Chi 108 Military Central Hospital
  • Nguyen Binh An 108 Military Central Hospital
  • Le Ngoc Ha 108 Military Central Hospital

Main Article Content


Hepatocellular carcinoma, treatment planning, radioembolization, 90Y resin microspheres, 99mTc-MAA SPECT/CT, 90Y PET/CT

Tóm tắt

Objective: The purpose of our study is to validate the utility of 90Y PET/CT compared to SPECT/CT simulation in dosimetry and prediction of treatment response. Subject and method: Thirty-four consecutive hepatocellular carcinoma (HCC) patients, intermediate and advanced stage who underwent 90Y resin microsphere transarterial embolization (TARE) were recruited in the study. Lung shunt fraction (LSF), tumor to-normal liver uptake ratio (TNr) and absorbed dose for target tumors were estimated on 99m Tc-MAA SPECT/CT and 90Y PET/CT. The patients were followed up after treatment within 3 months (2.8 ± 0.84 months) on contrast-enhanced CT to assess treatment response using mRECIST criteria. Result: The imaging characteristics including heterogeneity, necrosis and thrombosis uptake were better delineated on PET/CT imaging than SPECT/CT. The agreement and correlation of TNr on PET/CT and SPECT/CT were stronger. Dose delivery to tumor (Dtumor) threshold of 125Gy estimated on 99mTc-MAA SPECT/CT was more accurate than PET/CT for prediction of treatment response after 90Y-radioembolization in HCC patients with sensitivity of 87.5% and specificity of 90%. Conclusion: 99mTc-MAA SPECT/CT is superior to PET/CT to predict treatment response after 90Y resin microsphere treatment.

Article Details

Các tài liệu tham khảo

1. Zhu RX, Seto WK, Lai CL, Yuen MF (2016) Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut and liver 10(3): 332-339.
2. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 138(1): 52-64.
3. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C et al (2010) The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 51(8): 1206-1212.
4. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F et al (2011) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38(7): 1393-1406.
5. Gil‐Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez‐Fraile M, Rodriguez J et al (2013) Prognostic factors and prevention of radioembolization‐induced liver disease. Hepatology (Baltimore, Md) 57(3): 1078-1087.
6. Gates VL, Esmail AA, Marshall K, Spies S, Salem R (2011) Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: Proof of concept. J Nucl Med 52(1): 72-76.
7. Kim MN, Kim BK, Han KH, Kim SU (2015) Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: Considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 9(3): 335-348.
8. Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul J-L, Ardisson V et al (2012) Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. European Journal of Nuclear Medicine and Molecular Imaging 39(5): 872-880.
9. Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H et al (2011) Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: Phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nucl Med Commun 32(12): 1245-1255.
10. Garin E, Rolland Y, Laffont S, Edeline J (2016) Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. European Journal of Nuclear Medicine and Molecular Imaging 43: 559-575.
11. Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H et al (2017) High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. Liver Int 37(1): 101-110.
12. Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH et al (2012) Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med 53(4): 559-566.